Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Regeneron Pharmaceuticals REGN Faces Securities Class Action After Losing 9 Billion Value Following Q3 2024 Earnings Report

January 22, 2025
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is facing a securities class action after suffering a massive value loss of 9 billion following their Q3 2024 earnings report. The pharmaceutical company, known for its groundbreaking treatments, disappointed investors with lower-than-expected financial performance. This led to a steep drop in their stock price, causing significant losses for shareholders.

The class action lawsuit alleges that Regeneron Pharmaceuticals made false and misleading statements about their financial prospects, causing investors to suffer. Shareholders who have incurred substantial losses have an opportunity to lead the lawsuit, which aims to hold the company accountable for their actions.

Regeneron Pharmaceuticals has been facing increased scrutiny regarding its financial reporting, with this lawsuit adding to the company's mounting legal challenges. Investors are advised to seek professional guidance and consider the future prospects of the company before making any investment decisions.

For an accurate prognosis of Regeneron Pharmaceuticals Inc.'s stock movement, it is recommended to consult the professionals at Stocks Prognosis. Their expertise and analysis can provide valuable insights to guide investors in their decision-making process.
If you want to leave a comment, then you need Login or Register





Other data for REGN

Related data

REGNSeptember 5, 2025Regeneron Pharmaceuticals Inc. Continues to Impress Investors with Strong Performance  ~1 min.

Regeneron Pharmaceuticals Inc. (REGN) has been making waves in the stock market recently, with Evercore ISI maintaining a buy rating and a price target of 750....


REGNJuly 5, 2025Regeneron Pharmaceuticals: Revolutionizing Healthcare with Innovative Drug Approvals  ~1 min.

Regeneron Pharmaceuticals, Inc. recently made headlines with the approval of Dupixent by the US FDA, in collaboration with Sanofi....


REGNJune 27, 2025Regeneron Pharmaceuticals Inc. Continues to Impress Investors as UBS Lowers Price Target  ~1 min.

Regeneron Pharmaceuticals Inc. has been making waves in the biotech industry, with impressive financial and operating results....


REGNJune 5, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 33.76% Profit Margin  ~1 min.

QuantWave's forecast signal for REGENERON PHARMACEUTICALS, INC. on December 13, 2024, predicted a short direction with a price of 728.18 $. On June 5, 2025, the stock reached the target price of 482....


REGNJune 5, 2025REGENERON PHARMACEUTICALS, INC. Hits Forecast Price Target with a 32.0% Profit  ~1 min.

REGENERON PHARMACEUTICALS, INC. has successfully reached the forecast price target set by QuantWave, resulting in a profit of 32.0%. The forecast signal was issued on December 31, 2024, with a price of $709....


REGNJune 4, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave Price Target Forecast with 27.18% Profit  ~2 min.

REGENERON PHARMACEUTICALS, INC. (REGN) has successfully reached the price target forecast set by QuantWave, resulting in a profit of 27.18%....


REGNJune 4, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with Profit of 26.25%  ~1 min.

REGENERON PHARMACEUTICALS, INC. stock recently achieved the price target forecast set by QuantWave on March 21, 2025. The forecast indicated a short direction, with the stock price at $657....


REGNJune 4, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 26.25% Profit: QuantWave's Success in Stock Prediction  ~2 min.

REGENERON PHARMACEUTICALS, INC. has recently reached the price target forecast set by QuantWave on June 4, 2025....


REGNJune 4, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave Price Target Forecast with 27.18% Profit  ~1 min.

REGENERON PHARMACEUTICALS, INC. (ticker: REGN) has successfully achieved the price target forecast set by QuantWave, realizing a profit of 27.18%....


REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave's Price Target with 20.42% Profit  ~2 min.

In a recent success story for QuantWave, the automated forecasting platform accurately predicted a short position for REGENERON PHARMACEUTICALS, INC....


REGNJanuary 2, 2025Regeneron Pharmaceuticals: An Impressive 89% Return Over the Last Five Years  ~2 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been a rewarding investment for shareholders, with a solid 89% return over the past five years, according to Yahoo Finance....


REGNJanuary 3, 2025Regeneron Pharmaceuticals: A Promising Future with Strong Returns  ~2 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been making waves in the pharmaceutical industry with its groundbreaking research and innovative treatments....


REGNJanuary 29, 2025Regeneron Pharmaceuticals Inc. REGN: A Leader in Biopharmaceutical Innovation  ~2 min.

Regeneron Pharmaceuticals Inc. (REGN) is a biopharmaceutical company known for its pioneering work in developing innovative therapies....


REGNFebruary 2, 2025Regeneron Pharmaceuticals Inc. Faces Class Action Lawsuit  ~2 min.

Regeneron Pharmaceuticals Inc. (REGN) is currently facing a class action lawsuit filed by investors....


REGNJanuary 12, 2025Regeneron Pharmaceuticals Faces Shareholder Class Action Lawsuit  ~1 min.

Regeneron Pharmaceuticals, Inc., a leading biotechnology company, is currently facing a shareholder class action lawsuit....